Radiolabelled 5′-iodo-2′-deoxyuridine: a promising alternative to [18F]-2-fluoro-2-deoxy-d-glucose for PET studies of early response to anticancer treatment
- 31 August 1999
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 26 (6) , 667-672
- https://doi.org/10.1016/s0969-8051(99)00039-6
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Imaging proliferation in vivo with [F-18]FLT and positron emission tomographyNature Medicine, 1998
- Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapyBreast Cancer Research and Treatment, 1998
- Kinetics of [methyl-11C]Thymidine in Patients with Squamous Cell Carcinoma of the Head and NeckActa Oncologica, 1996
- Radiolabeling kit/generator for 5-radiohalogenated uridinesJournal of Labelled Compounds and Radiopharmaceuticals, 1994
- Uptake and distribution of L-3-[I-125] Iodo-?-methyl tyrosine in experimental rat tumours: comparison with blood flow and growth rateEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993
- Metabolic changes of glioma following chemotherapy: an experimental study using four PET tracersJournal of Neuro-Oncology, 1992
- Radiation effects on uptake of 99Tcm-hexamethylpropylen amine oxime (HMPAO) in head and neck tumoursBritish Journal of Cancer, 1991
- 99mTc-HMPAO as a tumour blood flow agentEuropean Journal of Nuclear Medicine and Molecular Imaging, 1987
- Iodine-123-iododeoxyuridine: A potential indicator of tumour response to treatmentInternational Journal of Nuclear Medicine and Biology, 1980